Understand the source comparison
Best IGF-1 LR3 Supplier: Quality Comparison
Selecting the best IGF-1 LR3 supplier requires comparing specific quality markers that directly impact research outcomes. The table below evaluates key differentiation factors across supplier categories based on synthesis methods, documentation standards, and
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Selecting the best IGF-1 LR3 supplier requires comparing specific quality markers that directly impact research outcomes. The table below evaluates key differentiation factors across supplier categories based on synthesis methods, documentation standards, and purity verification protocols.
- Research-Grade (e.g., Real Peptides)
- HPLC + MS on every batch; third-party testing available; endotoxin <1.0 EU/mg
- Batch-specific COA with chromatogram, synthesis date, and retained sample tracking
- Temperature-logged shipping with 48-hour cold maintenance; replacement guarantee for excursions
- Small-batch SPPS (1–10g); multiple purification passes; >98% purity target
- Highest consistency and reproducibility; suitable for publication-grade research and longitudinal studies requiring batch-to-batch matching
- Mid-Tier Commercial
- HPLC on representative batches; MS available on request; endotoxin testing not standard
- Generic COA; synthesis date may be estimated; limited retained sample access
- Insulated packaging; no temperature monitoring; cold packs included
- Mixed-batch synthesis (10–50g); single purification pass; 95–98% purity typical
- Acceptable for preliminary research and protocol development; batch variability may affect reproducibility in dose-response studies
- Budget/Grey Market
- Supplier-provided COA only; purity claims not independently verified; no endotoxin data
- Generic or absent documentation; no synthesis date; no chromatographic data
- Standard shipping; no cold chain verification; product replacement unlikely
- Large-batch or contract synthesis source unknown; purity 85–95%; deletion sequences common
- High risk for experimental failure; unsuitable for publication-grade work; frequent batch inconsistencies and contamination reports
- Compounding Pharmacy (Clinical)
- USP standards; batch-tested per FDA 503B requirements; human-grade purity
- Full pharmaceutical documentation; lot tracking; expiration dating
- Pharmacy-grade cold chain; documented temperature control
- Clinical compounding standards; sterile preparation; intended for prescription use
- Not available for research purchase; requires prescription; regulatory framework designed for patient use, not laboratory protocols